BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 20028869)

  • 1. Elimination of human lung cancer stem cells through targeting of the stem cell factor-c-kit autocrine signaling loop.
    Levina V; Marrangoni A; Wang T; Parikh S; Su Y; Herberman R; Lokshin A; Gorelik E
    Cancer Res; 2010 Jan; 70(1):338-46. PubMed ID: 20028869
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A juxtacrine/paracrine loop between C-Kit and stem cell factor promotes cancer stem cell survival in epithelial ovarian cancer.
    Mazzoldi EL; Pavan S; Pilotto G; Leone K; Pagotto A; Frezzini S; Nicoletto MO; Amadori A; Pastò A
    Cell Death Dis; 2019 May; 10(6):412. PubMed ID: 31138788
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling.
    Warshamana-Greene GS; Litz J; Buchdunger E; Hofmann F; García-Echeverría C; Krystal GW
    Mol Cancer Ther; 2004 May; 3(5):527-35. PubMed ID: 15141010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. KIT receptor activation by autocrine and paracrine stem cell factor stimulates growth of merkel cell carcinoma in vitro.
    Krasagakis K; Fragiadaki I; Metaxari M; Krüger-Krasagakis S; Tzanakakis GN; Stathopoulos EN; Eberle J; Tavernarakis N; Tosca AD
    J Cell Physiol; 2011 Apr; 226(4):1099-109. PubMed ID: 20857409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regulation of cellular proliferation, cytoskeletal function, and signal transduction through CXCR4 and c-Kit in small cell lung cancer cells.
    Kijima T; Maulik G; Ma PC; Tibaldi EV; Turner RE; Rollins B; Sattler M; Johnson BE; Salgia R
    Cancer Res; 2002 Nov; 62(21):6304-11. PubMed ID: 12414661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. c-Kit is preferentially expressed in MYCN-amplified neuroblastoma and its effect on cell proliferation is inhibited in vitro by STI-571.
    Vitali R; Cesi V; Nicotra MR; McDowell HP; Donfrancesco A; Mannarino O; Natali PG; Raschellà G; Dominici C
    Int J Cancer; 2003 Aug; 106(2):147-52. PubMed ID: 12800187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Imatinib inhibits c-Kit-induced hypoxia-inducible factor-1alpha activity and vascular endothelial growth factor expression in small cell lung cancer cells.
    Litz J; Krystal GW
    Mol Cancer Ther; 2006 Jun; 5(6):1415-22. PubMed ID: 16818499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
    Abrams TJ; Lee LB; Murray LJ; Pryer NK; Cherrington JM
    Mol Cancer Ther; 2003 May; 2(5):471-8. PubMed ID: 12748309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The stem cell factor/c-kit receptor pathway enhances proliferation and invasion of pancreatic cancer cells.
    Yasuda A; Sawai H; Takahashi H; Ochi N; Matsuo Y; Funahashi H; Sato M; Okada Y; Takeyama H; Manabe T
    Mol Cancer; 2006 Oct; 5():46. PubMed ID: 17044945
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-Kit mediates chemoresistance and tumor-initiating capacity of ovarian cancer cells through activation of Wnt/β-catenin-ATP-binding cassette G2 signaling.
    Chau WK; Ip CK; Mak AS; Lai HC; Wong AS
    Oncogene; 2013 May; 32(22):2767-81. PubMed ID: 22797058
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Imatinib sensitizes endometrial cancer cells to cisplatin by targeting CD117-positive growth-competent cells.
    Zhang X; Kyo S; Nakamura M; Mizumoto Y; Maida Y; Bono Y; Takakura M; Fujiwara H
    Cancer Lett; 2014 Apr; 345(1):106-14. PubMed ID: 24333732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lung cancer stem cells as a target for therapy.
    Gorelik E; Lokshin A; Levina V
    Anticancer Agents Med Chem; 2010 Feb; 10(2):164-71. PubMed ID: 20184538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Potential use of imatinib in Ewing's Sarcoma: evidence for in vitro and in vivo activity.
    Merchant MS; Woo CW; Mackall CL; Thiele CJ
    J Natl Cancer Inst; 2002 Nov; 94(22):1673-9. PubMed ID: 12441322
    [TBL] [Abstract][Full Text] [Related]  

  • 14. E7080, a novel inhibitor that targets multiple kinases, has potent antitumor activities against stem cell factor producing human small cell lung cancer H146, based on angiogenesis inhibition.
    Matsui J; Yamamoto Y; Funahashi Y; Tsuruoka A; Watanabe T; Wakabayashi T; Uenaka T; Asada M
    Int J Cancer; 2008 Feb; 122(3):664-71. PubMed ID: 17943726
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Stem cell factor/c-kit signaling mediated cardiac stem cell migration via activation of p38 MAPK.
    Kuang D; Zhao X; Xiao G; Ni J; Feng Y; Wu R; Wang G
    Basic Res Cardiol; 2008 May; 103(3):265-73. PubMed ID: 18087667
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Roles of stem cell factor/c-Kit and effects of Glivec/STI571 in human uveal melanoma cell tumorigenesis.
    Lefevre G; Glotin AL; Calipel A; Mouriaux F; Tran T; Kherrouche Z; Maurage CA; Auclair C; Mascarelli F
    J Biol Chem; 2004 Jul; 279(30):31769-79. PubMed ID: 15145934
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A human monoclonal antibody targeting the stem cell factor receptor (c-Kit) blocks tumor cell signaling and inhibits tumor growth.
    Lebron MB; Brennan L; Damoci CB; Prewett MC; O'Mahony M; Duignan IJ; Credille KM; DeLigio JT; Starodubtseva M; Amatulli M; Zhang Y; Schwartz KD; Burtrum D; Balderes P; Persaud K; Surguladze D; Loizos N; Paz K; Kotanides H
    Cancer Biol Ther; 2014 Sep; 15(9):1208-18. PubMed ID: 24921944
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II trial of imatinib maintenance therapy after irinotecan and cisplatin in patients with c-Kit-positive, extensive-stage small-cell lung cancer.
    Schneider BJ; Kalemkerian GP; Ramnath N; Kraut MJ; Wozniak AJ; Worden FP; Ruckdeschel JC; Zhang X; Chen W; Gadgeel SM
    Clin Lung Cancer; 2010 Jul; 11(4):223-7. PubMed ID: 20630823
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imatinib mesylate (STI571) enhances amrubicin-induced cytotoxic activity through inhibition of the phosphatidylinositol 3-kinase/Akt pathway in small cell lung cancer cells.
    Suyama H; Igishi T; Ueda Y; Shigeoka Y; Kodani M; Morita M; Takeda K; Sumikawa T; Nakazaki H; Matsunami K; Matsumoto S; Shimizu E
    Oncol Rep; 2010 Jan; 23(1):217-22. PubMed ID: 19956885
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of imatinib mesylate on neuroblastoma tumorigenesis and vascular endothelial growth factor expression.
    Beppu K; Jaboine J; Merchant MS; Mackall CL; Thiele CJ
    J Natl Cancer Inst; 2004 Jan; 96(1):46-55. PubMed ID: 14709738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.